HIL-214 is under clinical development by HilleVax and currently in Phase II for Gastroenteritis. According to GlobalData, Phase II drugs for Gastroenteritis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HIL-214 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HIL-214 overview
HIL-214 is under development for the prevention of acute gastroenteritis caused by norovirus. The vaccine candidate is administered through intramuscular route as a suspension. It is a norovirus GI.1/GII 4 bivalent virus-like particle (VLP) vaccine adjuvanted with monophosphoryl lipid A (MPL) and aluminum hydroxide (AlOH). MPL increases the vaccine’s immunogenic effect.
It was under development for the prevention of acute gastroenteritis caused by norovirus.
HilleVax overview
HilleVax is a biopharmaceutical company that develop vaccine to protect against norovirus infection. The company is headquartered in United States.
For a complete picture of HIL-214’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
